MacroGenics, Inc.

MacroGenics, Inc.

MacroGenics, Inc.

Overview
Date Founded

2000

Headquarters

9704 Medical Center Drive,Rockville, MD 20850-3368

Type of Company

Public

Employees (Worldwide)

384

Industries

Pharmaceuticals
Hospitals & Patient Services
Industrial Machinery & Manufacturing
Biotechnology

Company Description

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

Contact Data
Trying to get in touch with decision makers at MacroGenics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Senior Vice President, Chief Financial Officer & Secretary

General Counsel

Senior Vice President, Research & Chief Scientific Officer

Senior Vice President, Clinical Development & Chief Medical Officer

Vice President, Controller & Treasurer

Senior Vice President, Business Development & Portfolio Management & Chief Business Officer

Senior Vice President, BioPharmaceutical Development & Manufacturing

Vice President-Human Resources & Facilities

Senior Director

Board of Directors

Former President & Chief Executive Officer at Novartis Corporation

Co-Founder at MacroGenics, Inc.

Venture Partner at Genesys Capital Partners, Inc.

Chairman at ViewPoint Therapeutics, Inc.

Chief Biotechnology Officer at Janssen Research & Development LLC

Former Head-Oncology Therapeutic Area at Takeda Oncology Co.

Former Chief Executive Officer at Celator Pharmaceuticals, Inc.

Consultant at Sunesis Pharmaceuticals, Inc.

Paths to MacroGenics, Inc.
Potential Connections via
Relationship Science
You
MacroGenics, Inc.
Owners & Shareholders
Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Details Hidden

Ra Capital Management LP seeks investment opportunities in private companies located in the US. The firm targets healthcare and life science companies. They provides financing for seed stage capital requirements. They acts as a lead investor and also makes follow-on investments.

Details Hidden

Consonance Capital Management's (CCM) funds seek to deliver exceptional, uncorrelated risk adjusted returns. CCM seeks to meet this objective by focusing on investment opportunities in the publicly traded stocks of healthcare companies. The firm invests in all sub-sectors of the healthcare sector including healthcare information technology, managed care, pharmaceuticals, specialty pharmaceuticals, commercial stage biotechnology, healthcare facilities and services, medical devices and supplies, diagnostics and consumer-based healthcare companies.CCM believes the public healthcare market lends itself to an active long/short strategy. The firm focuses on creating long and short portfolios driven by the opportunity for absolute return and alpha creation. The funds also invest in other types of securities and may use a variety of investment techniques to generate profit and/or control risk. These may include participating in swaps, buying or selling futures contracts, purchasing and writing options and other derivative contracts, purchasing or selling debt instruments, and trading on margin by borrowing funds and pledging securities as collateral. CCM invests primarily in healthcare companies in the US, and on an opportunistic basis in the rest of the world.^

Recent Transactions
Details Hidden

MacroGenics, Inc. issued USD Common Stock

Details Hidden

MacroGenics, Inc. issued USD Common Stock

Details Hidden

MacroGenics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onMacroGenics, Inc. issued USD Common Stock

Underwriter

Advised onMacroGenics, Inc. issued USD Common Stock

Underwriter

Advised onMacroGenics, Inc. issued USD Common Stock

Director

Advised onMacroGenics, Inc. issued USD Common Stock

Underwriter

Advised onMacroGenics, Inc. issued USD Common Stock

Managing Director, Biotechnology

Advised onMacroGenics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Kirkland & Ellis LLP

Legal Advisor

Attorney at Arnold & Porter LLP

Legal Advisor

Former Partner at Arnold & Porter LLP

Clients

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

Key Stats and Financials As of 2019
Market Capitalization
$1.24B
Total Enterprise Value
$338M
Earnings Per Share
$-3.16
Three Year Compounded Annual Growth Rate Of Revenue
-11.27%
EBITDA
$-165M
Total Debt
$30.6M
Debt TEV
0.09x
TEVNet Income
-2.23x
Enterprise Value / Sales
5.27x
EBITDAMargin
-256.88%
Revenue
$64.2M
Net Profit
$-152M
Total Equity
$231M
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Investors
Details Hidden

Clarus Ventures focuses on investments in the life science industry. The firm's invests primarily in biopharmaceutical and medical technology companies. Clarus Ventures has particular expertise in research and development, commercialization, business development and operations management at the global level. The firm also makes investment in public company.

Details Hidden

Alta Partners Management Corp. specializes in investments in healthcare venture capital companies. The firm looks for Technology enabled solutions and services that improve delivery and quality of care with Strong entrepreneurs

Details Hidden

Founded in 1992, TPG specializes in recognizing value – or the potential for value – where others do not. Our contrarian philosophy, global reach, and deep investment and operational expertise set TPG apart from other firms. Our complementary asset classes offer a unique investment platform. TPG has an extensive global network and long-standing, on-the-ground presence in critical markets. TPG has built a strong international presence with 17 offices in 10 countries. We were one of the first U.S.-based private investment firms to establish significant operations in Asia and Europe, in 1994 and 1995 respectively.

Suppliers
Baxter International, Inc. Pharmaceuticals | Deerfield, IL

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2011 sales of $13.9 billion and has approximately 48,500 employees.

Ajinomoto Co., Inc. Food | Tokyo, Japan

Ajinomoto Co., Inc. engages in the manufacture, distribution, and sale of food products, amino acids, and pharmaceuticals. It operates through the following segments: Domestic Food Products, Overseas Food Products, Life Support, Healthcare and Others. The Domestic Food Products segment includes seasonings and processed foods, and frozen foods. The Overseas Food Products segment provides consumer foods, which include flavor seasonings and instant noodles; and umami seasonings for processed food manufacturers. The Life Support segment offers feed-use amino acids, amino acids for pharmaceuticals and foods, sweeteners, pharmaceutical fine chemicals, and specialty chemicals. The Healthcare segment handles medical foods and pharmaceuticals. The Others segment covers the packaging materials business, healthcare business, partnership business, logistics, and other services. The company was founded by Saburosuke Suzuki II on May 20, 1909 and is headquartered in Tokyo, Japan.

AGC, Inc. (Japan) Other Manufacturing | Tokyo, Japan

AGC, Inc. engages in the manufacture and sale of glass, electronic materials, and chemicals. It operates through the following segments: Glass, Electronics, Chemicals, Ceramics and Other. The Glass segment provides security glass, fire-resistant glass, heat insulating glass, and automotive glass. The Electronics segment offers glass for display panels, optical thin film products, opto-electronic materials, synthetic quartz products, semiconductor components, and lighting products. The Chemicals segment deals with chlor-alkali and urethane products, water and oil repellents, solvents, gases, and specialty chemicals. The Ceramics and Other segment includes ceramic products, logistics, and financial services. The company was founded by Toshiya Iwasaki on September 8, 1907 and is headquartered in Tokyo, Japan.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by MacroGenics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of MacroGenics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and MacroGenics, Inc..